SEC Form 4 · accession 0001209191-18-063581
ARROWHEAD PHARMACEUTICALS, INC. · ARWR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mauro Ferrari
Director
Period of report
Dec 18, 2018
Accepted (ET)
Dec 19, 2018 · 7:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000879407
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 18, 2018 | A | 3,459 | $0.00 | A | 16,227 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This balance reflects the cancellation of 50,000 restricted stock units that were previously granted and reported on January 1, 2017. Dr. Ferrari's employer limits the amount of compensation he can take, and as such, these restricted stock units were subsequently cancelled.